"Xanthine Oxidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria.
| Descriptor ID |
D014969
|
| MeSH Number(s) |
D08.811.682.047.928
|
| Concept/Terms |
Xanthine Oxidase- Xanthine Oxidase
- Oxidase, Xanthine
- Hypoxanthine Oxidase
- Oxidase, Hypoxanthine
- Purine-Xanthine Oxidase
- Oxidase, Purine-Xanthine
- Purine Xanthine Oxidase
- Hypoxanthine Dehydrogenase
- Dehydrogenase, Hypoxanthine
- Hypoxanthine-Xanthine Oxidase
- Hypoxanthine Xanthine Oxidase
- Oxidase, Hypoxanthine-Xanthine
|
Below are MeSH descriptors whose meaning is more general than "Xanthine Oxidase".
Below are MeSH descriptors whose meaning is more specific than "Xanthine Oxidase".
This graph shows the total number of publications written about "Xanthine Oxidase" by people in this website by year, and whether "Xanthine Oxidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xanthine Oxidase" by people in Profiles.
-
HIF-1a activation by intermittent hypoxia requires NADPH oxidase stimulation by xanthine oxidase. PLoS One. 2015; 10(3):e0119762.
-
Effects of Smilaxchinoside A and Smilaxchinoside C, two steroidal glycosides from Smilax riparia, on hyperuricemia in a mouse model. Phytother Res. 2014 Dec; 28(12):1822-8.
-
Xanthine oxidase mediates hypoxia-inducible factor-2a degradation by intermittent hypoxia. PLoS One. 2013; 8(10):e75838.
-
Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov; 15(11):1049-55.
-
Xanthine oxidase-derived ROS upregulate Egr-1 via ERK1/2 in PA smooth muscle cells; model to test impact of extracellular ROS in chronic hypoxia. PLoS One. 2011; 6(11):e27531.
-
Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009 Mar; 21(2):143-9.
-
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol. 2010 Jul 23; 142(3):279-87.
-
Mechanical stress activates xanthine oxidoreductase through MAP kinase-dependent pathways. Am J Physiol Lung Cell Mol Physiol. 2006 Sep; 291(3):L345-53.
-
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4.
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08; 353(23):2450-61.